TSP1-CD47 signaling is upregulated in clinical pulmonary hypertension and contributes to pulmonary arterial vasculopathy and dysfunction

Cardiovascular Research

Volumn 113, Issue 1, 2017, Pages 15-29

  Rogers, Natasha M ^a,b   Sharifi Sanjani, Maryam ^a   Yao, Mingyi ^c   Ghimire, Kedar ^a   Bienes Martinez, Raquel ^a   Mutchler, Stephanie M ^a   Knupp, Heather E ^a   Baust, Jeffrey ^a   Novelli, Enrico M ^a   Ross, Mark ^a   Croix, Claudette S ^a   Kutten, Johannes C ^a   Czajka, Caitlin A ^a   Sembrat, John C ^a,b   Rojas, Mauricio ^a,b   Labrousse Arias, David ^d   Bachman, Timothy N ^a   Vanderpool, Rebecca R ^a   Zuckerbraun, Brian S ^a   Champion, Hunter C ^a   Mora, Ana L ^a   Straub, Adam C ^a   Bilonick, Richard A ^a   Calzada, Maria J ^d   Isenberg, Jeffrey S ^a   more..

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

CD47; Clinical pulmonary hypertension; CMyc; ET 1; Thrombospondin 1

Indexed keywords

BLOCKING ANTIBODY; CD47 ANTIGEN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; MONOCROTALINE; OX 101; SMALL INTERFERING RNA; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; VASODILATOR AGENT; CD47 PROTEIN, HUMAN; CD47 PROTEIN, MOUSE; MYC PROTEIN; MYC PROTEIN, HUMAN; MYC PROTEIN, MOUSE; THROMBOSPONDIN-1, HUMAN; THROMBOSPONDIN-1, MOUSE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; GENE INDUCTION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; LUNG ALVEOLUS EPITHELIUM CELL; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; ONCOGENE C MYC; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INDUCTION; PULMONARY ARTERY; PULMONARY ARTERY SMOOTH MUSCLE CELL; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; RAT; SIGNAL TRANSDUCTION; UPREGULATION; VASOCONSTRICTION; VASODILATATION; AGED; ANIMAL; ARTERIAL PRESSURE; C57BL MOUSE; CASE CONTROL STUDY; CELL LINE; DEFICIENCY; DISEASE MODEL; ENDOTHELIUM CELL; FEMALE; GENETIC PREDISPOSITION; GENETICS; HYPERTENSION, PULMONARY; KNOCKOUT MOUSE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHENOTYPE; RNA INTERFERENCE; YOUNG ADULT;

ADULT; AGED; ANIMALS; ANTIGENS, CD47; ARTERIAL PRESSURE; CASE-CONTROL STUDIES; CELL LINE; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ENDOTHELIN-1; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION, PULMONARY; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-MYC; PULMONARY ARTERY; RATS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THROMBOSPONDIN 1; TRANSFECTION; UP-REGULATION; VASOCONSTRICTION; VASODILATION; YOUNG ADULT;

EID: 85016008915     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvw218     Document Type: Article

References (72)

1. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, Levy PS, Pietra GG, Reid LM, Reeves JT, Rich S, Vreim CE, Williams GW, Wu M. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-349.
2. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2008;118:2372-2379.
3. Shao D, Park JE, Wort SJ. The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension. Pharmacol Res 2011;63:504-511.
4. Erol A. Deciphering the intricate regulatory mechanisms for the cellular choice between cell repair, apoptosis or senescence in response to damaging signals. Cell Signal 2011;23:1076-1081.
5. Ho R, Chronis C, Plath K. Mechanistic insights into reprogramming to induced pluripotency. J Cell Physiol 2011;226:868-878.
6. Adams JC, Lawler J. The thrombospondins. Cold Spring Harbor Perspect Biol 2011;3:a009712.
7. Roberts DD, Miller TW, Rogers NM, Yao M, Isenberg JS. The matricellular protein thrombospondin-1 globally regulates cardiovascular function and responses to stress via CD47. Matrix Biol 2012;31:162-169.
8. Calzada MJ, Zhou L, Sipes JM, Zhang J, Krutzsch HC, Iruela-Arispe ML, Annis DS, Mosher DF, Roberts DD. Alpha4beta1 integrin mediates selective endothelial cell responses to thrombospondins 1 and 2 in vitro and modulates angiogenesis in vivo. Circ Res 2004;94:462-470.
9. Bauer PM, Bauer EM, Rogers NM, Yao M, Feijoo-Cuaresma M, Pilewski JM, Champion HC, Zuckerbraun BS, Calzada MJ, Isenberg JS. Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1. Cardiovasc Res 2012;93:682-693.
10. Labrousse-Arias D, Castillo-Gonzalez R, Rogers NM, Torres-Capelli M, Barreira B, Aragones J, Cogolludo A, Isenberg JS, Calzada MJ. HIF-2alpha-mediated induction of pulmonary thrombospondin-1 contributes to hypoxia-driven vascular remodeling and vasoconstriction. Cardiovasc Res 2016;109:115-130.
11. Ochoa CD, Yu L, Al-Ansari E, Hales CA, Quinn DA. Thrombospondin-1 null mice are resistant to hypoxia-induced pulmonary hypertension. J Cardiothorac Surg 2010;5:32.
12. Helkin A, Maier KG, Gahtan V. Thrombospondin-1,-2 and-5 have differential effects on vascular smooth muscle cell physiology. Biochem Biophys Res Commun 2015;464:1022-1027.
13. Isenberg JS, Annis DS, Pendrak ML, Ptaszynska M, Frazier WA, Mosher DF, Roberts DD. Differential interactions of thrombospondin-1,-2, and-4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chem 2009;284:1116-1125.
14. Isenberg JS, Roberts DD, Frazier WA. CD47: A new target in cardiovascular therapy. Arterioscler Thromb Vasc Biol 2008;28:615-621.
15. Isenberg JS, Ridnour LA, Perruccio EM, Espey MG, Wink DA, Roberts DD. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMPdependent manner. Proc Natl Acad Sci U S A 2005;102:13141-13146.
16. Isenberg JS, Ridnour LA, Dimitry J, Frazier WA, Wink DA, Roberts DD. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 2006;281:26069-26080.
17. Isenberg JS, Hyodo F, Matsumoto K, Romeo MJ, Abu-Asab M, Tsokos M, Kuppusamy P, Wink DA, Krishna MC, Roberts DD. Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood 2007;109:1945-1952.
18. Isenberg JS, Romeo MJ, Abu-Asab M, Tsokos M, Oldenborg A, Pappan L, Wink DA, Frazier WA, Roberts DD. Increasing survival of ischemic tissue by targeting CD47. Circ Res 2007;100:712-720.
19. Marelli-Berg FM, Peek E, Lidington EA, Stauss HJ, Lechler RI. Isolation of endothelial cells from murine tissue. J Immunol Methods 2000;244:205-215.
20. Bauer EM, Qin Y, Miller TW, Bandle RW, Csanyi G, Pagano PJ, Bauer PM, Schnermann J, Roberts DD, Isenberg JS. Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation. Cardiovasc Res 2010;88:471-481.
21. Yao M, Rogers NM, Csanyi G, Rodriguez AI, Ross MA, St Croix C, Knupp H, Novelli EM, Thomson AW, Pagano PJ, Isenberg JS. Thrombospondin-1 activation of signalregulatory protein-alpha stimulates reactive oxygen species production and promotes renal ischemia reperfusion injury. J Am Soc Nephrol 2014;25:1171-1186.
22. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. 2015, Vienna.
23. Ioannis Kosmidis. brglm: Bias reduction in binomial-response 2013, Generalized Linear Models.
24. Novelli EM, Kato GJ, Ragni MV, Zhang Y, Hildesheim ME, Nouraie M, Barge S, Meyer MP, Hassett AC, Gordeuk VR, Gladwin MT, Isenberg JS. Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates. Am J Hematol 2012;87:326-330.
25. Smadja DM, d'Audigier C, Bieche I, Evrard S, Mauge L, Dias JV, Labreuche J, Laurendeau I, Marsac B, Dizier B, Wagner-Ballon O, Boisson-Vidal C, Morandi V, Duong-Van-Huyen JP, Bruneval P, Dignat-George F, Emmerich J, Gaussem P. Thrombospondin-1 is a plasmatic marker of peripheral arterial disease that modulates endothelial progenitor cell angiogenic properties. Arterioscler Thromb Vasc Biol 2011;31:551-559.
26. Heinze G, Schemper M. A solution to the problem of separation in logistic regression. Stat Med 2002;21:2409-2419.
27. Rabinovitch M. Pathobiology of pulmonary hypertension. Extracellular matrix. Clin Chest Med 2001;22:433-449.
28. Schreier D, Hacker T, Song G, Chesler N. The role of collagen synthesis in ventricular and vascular adaptation to hypoxic pulmonary hypertension. J Biomech Eng 2013;135:021018.
29. Azuma A, Li YJ, Abe S, Usuki J, Matsuda K, Henmi S, Miyauchi Y, Ueda K, Izawa A, Sone S, Hashimoto S, Kudoh S. Interferon-{beta} inhibits bleomycin-induced lung fibrosis by decreasing transforming growth factor-{beta} and thrombospondin. Am J Respir Cell Mol Biol 2005;32:93-98.
30. Chen Y, Leask A, Abraham DJ, Kennedy L, Shi-Wen X, Denton CP, Black CM, Verjee LS, Eastwood M. Thrombospondin 1 is a key mediator of transforming growth factor beta-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanism. Fibrogenesis Ttissue Repair 2011;4:9.
31. Hotchkiss KA, Basile CM, Spring SC, Bonuccelli G, Lisanti MP, Terman BI. TEM8 expression stimulates endothelial cell adhesion and migration by regulating cellmatrix interactions on collagen. Exp Cell Res 2005;305:133-144.
32. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:40S-47S.
33. Chemla D, Castelain V, Herve P, Lecarpentier Y, Brimioulle S. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J 2002;20:1314-1331.
34. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000;16:653-699.
35. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004;61:227-237.
36. Lopes AA, Maeda NY, Almeida A, Jaeger R, Ebaid M, Chamone DF. Circulating platelet aggregates indicative of in vivo platelet activation in pulmonary hypertension. Angiology 1993;44:701-706.
37. Schulman LL, Grossman BA, Owen J. Platelet activation and fibrinopeptide formation in pulmonary hypertension. Chest 1993;104:1690-1693.
38. Disdier M, Legrand C, Bouillot C, Dubernard V, Pidard D, Nurden AT. Quantitation of platelet fibrinogen and thrombospondin in Glanzmann's thrombasthenia by electroimmunoassay. Throm Res 1989;53:521-533.
39. Eilers M, Picard D, Yamamoto KR, Bishop JM. Chimaeras of myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells. Nature 1989;340:66-68.
40. Patel JH, McMahon SB. Targeting of Miz-1 is essential for Myc-mediated apoptosis. J Biol Chem 2006;281:3283-3289.
41. Takahashi H, Soma S, Muramatsu M, Oka M, Ienaga H, Fukuchi Y. Discrepant distribution of big endothelin (ET)-1 and ET receptors in the pulmonary artery. Eur Respir J 2001;18:5-14.
42. Marciniak SJ, Plumpton C, Barker PJ, Huskisson NS, Davenport AP. Localization of immunoreactive endothelin and proendothelin in the human lung. Pulm Pharmaco 1992;5:175-182.
43. Grignola JC, Gines F, Bia D, Armentano R. Improved right ventricular-vascular coupling during active pulmonary hypertension. Int J Cardiol 2007;115:171-182.
44. Overbeek MJ, Mouchaers KT, Niessen HM, Hadi AM, Kupreishvili K, Boonstra A, Voskuyl AE, Belien JA, Smit EF, Dijkmans BC, Vonk-Noordegraaf A, Grunberg K. Characteristics of interstitial fibrosis and inflammatory cell infiltration in right ventricles of systemic sclerosis-associated pulmonary arterial hypertension. Int J Rheumatol 2010;2010.
45. Redout EM, van der Toorn A, Zuidwijk MJ, van de Kolk CW, van Echteld CJ, Musters RJ, van Hardeveld C, Paulus WJ, Simonides WS. Antioxidant treatment attenuates pulmonary arterial hypertension-induced heart failure. Am J Physiol Heart Circ Physiol 2010;298:H1038-H1047.
46. Sharifi-Sanjani M, Shoushtari AH, Quiroz M, Baust J, Sestito SF, Mosher M, Ross M, McTiernan CF, St Croix CM, Bilonick RA, Champion HC, Isenberg JS. Cardiac CD47 drives left ventricular heart failure through Ca2+-CaMKII-regulated induction of HDAC3. J Am Heart Assoc 2014;3:e000670.
47. Maxhimer JB, Shih HB, Isenberg JS, Miller TW, Roberts DD. Thrombospondin-1/CD47 blockade following ischemia-reperfusion injury is tissue protective. Plast Reconstr Surg 2009;124:1880-1889.
48. Maloney JP, Stearman RS, Bull TM, Calabrese DW, Tripp-Addison ML, Wick MJ, Broeckel U, Robbins IM, Wheeler LA, Cogan JD, Loyd JE. Loss-of-function thrombospondin-1 mutations in familial pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2012;302:L541-L554.
49. Armstrong LC, Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol 2003;22:63-71.
50. Green DE, Kang BY, Murphy TC, Hart CM. Peroxisome proliferator-activated receptor gamma (PPARgamma) regulates thrombospondin-1 and Nox4 expression in hypoxia-induced human pulmonary artery smooth muscle cell proliferation. Pulm Circ 2012;2:483-491.
51. Yang YJ, Zheng XW, Yang GL, Cheng DY, Zhang P. The expression of thrombospondin-1 in serum and pulmonary arterioles of hypoxic pulmonary hypertension rats. Sichuan da xue xue bao Yi xue ban. J Sichuan Univ Med Sci Ed 2012;43:839-842.
52. Malek MH, Olfert IM. Global deletion of thrombospondin-1 increases cardiac and skeletal muscle capillarity and exercise capacity in mice. Exp Physiol 2009;94:749-760.
53. Kaur S, Martin-Manso G, Pendrak ML, Garfield SH, Isenberg JS, Roberts DD. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem 2010;285:38923-38932.
54. Ridnour LA, Windhausen AN, Isenberg JS, Yeung N, Thomas DD, Vitek MP, Roberts DD, Wink DA. Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and-independent pathways. Proc Natl Acad Sci U S A 2007;104:16898-16903.
55. Csanyi G, Yao M, Rodriguez AI, Al Ghouleh I, Sharifi-Sanjani M, Frazziano G, Huang X, Kelley EE, Isenberg JS, Pagano PJ. Thrombospondin-1 regulates blood flow via CD47 receptor-mediated activation of NADPH oxidase 1. Arterioscler Thromb Vasc Biol 2012;32:2966-2973.
56. Kaur S, Soto-Pantoja DR, Stein EV, Liu C, Elkahloun AG, Pendrak ML, Nicolae A, Singh SP, Nie Z, Levens D, Isenberg JS, Roberts DD. Thrombospondin-1 signaling through CD47 inhibits self-renewal by regulating c-Myc and other stem cell transcription factors. Sci Rep 2013;3:1673.
57. Rogers NM, Zhang ZJ, Wang JJ, Thomson AW, Isenberg JS. CD47 regulates renal tubular epithelial cell self-renewal and proliferation following renal ischemia reperfusion. Kidney Int 2016;90:334-347.
58. Chester AH, Yacoub MH. The role of endothelin-1 in pulmonary arterial hypertension. Glob Cardiol Sci Pract 2014;2014:62-78.
59. Miyagawa K, Emoto N. Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension. Ther Advan Cardiovasc Dis 2014;8:202-216.
60. Nasser SA, El-Mas MM. Endothelin ETA receptor antagonism in cardiovascular disease. Eur J Pharmacol 2014;737:210-213.
61. Wu C, Wang S, Xu C, Tyler A, Li X, Andersson C, Oji Y, Sugiyama H, Chen Y, Li A. WT1 enhances proliferation and impedes apoptosis in KRAS mutant NSCLC via targeting cMyc. Cell Physiol Biochem 2015;35:647-662.
62. Miller TW, Soto-Pantoja DR, Schwartz AL, Sipes JM, DeGraff WG, Ridnour LA, Wink DA, Roberts DD. CD47 globally regulates metabolic pathways that control resistance to ionizing radiation. J Biol Chem 2015;290:24858-24874.
63. Rafikov R, Sun X, Rafikova O, Louise Meadows M, Desai AA, Khalpey Z, Yuan JX, Fineman JR, Black SM. Complex I dysfunction underlies the glycolytic switch in pulmonary hypertensive smooth muscle cells. Redox Biol 2015;6:278-286.
64. Tuder RM, Davis LA, Graham BB. Targeting energetic metabolism: A new frontier in the pathogenesis and treatment of pulmonary hypertension. Am J Respir Crit Care Med 2012;185:260-266.
65. Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, Torbicki A. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S55-S66.
66. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: The hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297:L1013-L1032.
67. Maarman G, Lecour S, Butrous G, Thienemann F, Sliwa K. A comprehensive review: The evolution of animal models in pulmonary hypertension research; are we there yet? Pulm Circ 2013;3:739-756.
68. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka M. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 2010;121:2747-2754.
69. Ciuclan L, Bonneau O, Hussey M, Duggan N, Holmes AM, Good R, Stringer R, Jones P, Morrell NW, Jarai G, Walker C, Westwick J, Thomas M. A novel murine model of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2011;184:1171-1182.
70. Lawrie A. A report on the use of animal models and phenotyping methods in pulmonary hypertension research. Pulm Circ 2014;4:2-9.
71. Isenberg JS, Jia Y, Fukuyama J, Switzer CH, Wink DA, Roberts DD. Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J Biol Chem 2007;282:15404-15415.
72. Yu J, Wilson J, Taylor L, Polgar P. DNA microarray and signal transduction analysis in pulmonary artery smooth muscle cells from heritable and idiopathic pulmonary arterial hypertension subjects. J Cell Biochem 2015;116:386-397.